Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 70

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 70
---
 OF CONTENTS

| COMPENSATION DISCUSSION AND ANALYSIS |

In setting these target bonus opportunities, the Committee determined that a higher target bonus opportunity for the Chief Executive Officer, relative to the other executive officers, was appropriate because of the position and responsibilities that our Chief Executive Officer holds. The Committee further determined that the target bonus opportunities for Mr. Nguyen and Mr. Smith (both at 50%) and Ms. Karp and Dr. Zago (both at 40%) continued to be appropriate based on a review of market factors, as well as, the corporate duties and responsibilities of each such officer.

For fiscal year 2024, the Committee (and the Board, with respect to Dr. Kinney) established pre-determined corporate objectives that it considered critical to the near- and long-term success of the Company. No payout would be earned if achievement of these objectives in the aggregate was below 60% of target. Those objectives were as set forth below, with the weightings shown. The Committee and Board considered these objectives as constituting an appropriate balance of being realistic but challenging, and that exceeding these objectives would, as a whole, require significant "stretch" performance.

| Objective                                                                                                                                                                                                                                                                             |     | Weighting |     | Result |
| Progress R&D portfolio to achieve primary 2024 milestones:                                                                                                                                                                                                                            |     | 95%       |     |        |
| For Birtamimab, reach decision re expansion of total enrollment in the AFFIRM-AL clinical trial; achieve an enrollment goal for the AFFIRM-AL clinical trial; execute engagement plan to support enrollment.                                                                          |     | 40%       |     | Met    |
| For PRX012, complete Phase 1 clinical trial through a specified cohort; execute communication plan to support positioning.                                                                                                                                                            |     | 45%       |     | Met    |
| For PRX019, obtain BMS option exercise and initiate Phase 1 clinical trial.                                                                                                                                                                                                           |     | 5%        |     | Met    |
| For novel platform, reach development decision based onin vivoresults; initiate additional activities based on such results.                                                                                                                                                          |     | 5%        |     | Met    |
| Meet cash burn guidance range and optimize shareholder base:                                                                                                                                                                                                                          |     | 5%        |     |        |
| Meet publicly-disclosed cash burn guidance range.                                                                                                                                                                                                                                     |     | 2.5%      |     | Met    |
| Optimize shareholder base by: retaining